Transdermal Therapeutic System of Isradipine: Effect of Hydrophilic and Hydrophobic Matrix on In Vitro and Ex vivo Characteristics

다국어 초록 (Multilingual Abstract)

Isradipine (ISDP) is an effective calcium channel blocker used in the treatment of hypertension. It undergoes extensive first pass metabolism and bioavailability through the oral route is only about 15 to 24%. Hence we attempted to develop a matrix type controlled transdermal drug delivery system for ISDP. Formulations A1, A2, A3 were composed of Eudragit RL100 and hydroxypropyl methyl cellulose (HPMC) in 1:3, 1:1, 3:1 ratios; A4, A5, A6 were composed of Eudragit RS100 and HPMC in 1:3, 1:1, 3:1 ratios. All six formulations carried 5 mg of ISDP/patch area, 5% v/w of D-limonene, 15 % v/w of propylene glycol in methanol:dichloromethane (1:1). The physicochemical compatibility of the drug and the polymers was studied by infrared spectroscopy and differential scanning calorimetry. The results suggested no physicochemical incompatibility between the drug and the polymers. The prepared transdermal drug delivery system were evaluated for physicochemical characteristics, mainly in vitro release and ex vivo permeation. The ex vivo permeation studies were carried out across excised rat skin using Franz diffusion cell. All the formulations exhibited satisfactory physicochemical characteristics. Cumulative amount of the drug released in 36 h from the six formulations were 1695.32, 1527.89, 1455.54, 1485.65, 1282.81 and 916.88 μg/cm2 respectively. Corresponding values for the cumulative amounts of drug permeated across the rat skin for the above matrix films were 1456.29, 1284.70, 1182.99, 1212.72, 1046.05, and 782.60 μg/cm2 respectively. By fitting the data into zero order, first order and Higuchi models, it was concluded that drug release from matrix films followed Higuchi model and the mechanism of drug release was diffusion mediated. Based on the physical evaluation, in vitro drug release and ex vivo permeation characteristics, it was concluded that for potential therapeutic use, monolithic drug matrix films A1, may be suitable for the development of a transdermal drug delivery system of ISDP.

참고문헌 (Reference)

1 Mamatha, T, "Transdermal drug delivery system for atomoxetine hydrochloride-in vitro and ex vivo evaluation" 3 : 188-196, 2009

2 Suwanpiodokkul, N, "Transdermal delivery of zidovidine (AZT): The effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin" 5 : e48-, 2004

3 Tokudome, Y, "The synergic effects of various electrolytes and electroporation on the in vitro skin permeation of calcein" 92 : 93-101, 2003

4 Ho, H. O, "The influence of cosolvents on the in-vitro percutaneous penetration of diclofenac sodium from a gel system" 46 : 636-642, 1994

5 El-Kattan, A. F, "The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities" 215 : 229-240, 2001

6 Nair, V. B, "The effect of pretreatment with terpenes on transdermal iontophoretic delivery of arginine vasopressin" 59 : 575-581, 2004

7 Sweetman, S. C, "The Complete Drug Reference. Martindale 34th edi" Pharmaceutical Press 942-, 2005

8 Williams, A. C, "Terpenes and lipid-proteinpartitioning theory of skin penetration enhancement" 8 : 17-24, 1991

9 Nishihata, T, "Percutaneous absorption of diclofenac in rats and humans: aqueous gel formulation" 46 : 1-7, 1988

10 Okabe, H, "Percutaneous absorption enhancing effect and skin irritation of monocyclic monoterpenes" 6 : 229-238, 1990

11 Barry, B. W, "Penetration enhancers: Dermatological formulations" Marcel Dekker 160-172, 1983

12 Santoyo, S, "Penetration enhancer effects on the in vitro percutaneous absorption of piroxicam through rat skin" 117 : 219-224, 1995

13 Moser, K, "Passive skin penetration enhancement and its quantification in vitro" 52 : 103-112, 2001

14 Barry, B. W, "Novel mechanisms and devices to enable successful transdermal drug delivery" 14 : 101-114, 2001

15 Costa, P, "Modeling and comparison of dissolution profiles" 13 : 123-133, 2001

16 Parsaee, S, "In vitro release of diclofenac diethylammonium from lipid-based formulations" 241 : 185-190, 2002

17 Krishnaiah, Y. S. R, "In vitro percutaneous permeability enhancement of nimodipine by limonene across the excised rat abdominal skin" 59 : 942-947, 2004

18 Zhao, K, "In vitro percutaneous absorption enhancement of propranolol hydrochloride through porcine epidermis by terpenes/ethanol" 62 : 359-366, 1999

19 Gao, S, "In vitro percutaneous absorption enhancement of a lipophilic drug tamoxifen by terpenes" 51 : 193-199, 1998

20 Wade, A, "Handbook of Pharmaceutical Excipients" American Pharmaceutical Publishing Association 252-406, 2000

21 Mutalic, S, "Glibenclamide transdermal patches:physicochemical, pharmacodynamic, and pharmacokinetic evaluations" 93 : 1577-1594, 2004

22 Al-Saidan, S. M, "Formulation of an HPMC gel drug reservoir system with ethanol-water as a solvent system and limonene as a penetration enhancer for enhancing in vitro transdermal delivery of nicorandil" 17 : 310-320, 2004

23 Rao, P. R, "Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration" 24 : 327-336, 1998

24 Ota, Y, "Evaluation of percutaneous absorption of midazolam by terpenes" 18 : 261-266, 2003

25 Okabe, H, "Effect of limonene and related compounds on the percutaneous absorption of indomethacin" 4 : 313-321, 1989

26 Monti, D, "Effect of different terpenecontaining essential oils on permeation of estradiol through hairless mouse skin" 237 : 209-214, 2002

27 Bodmeier, R, "Drug release from laminated polymeric films prepared from aqueous latexes" 79 : 32-36, 1990

28 Gupta, R, "Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone-ethyl cellulose matrices" 29 : 1-7, 2003

29 Arora, P, "Design, development, physicochemical and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt" 91 : 2076-2089, 2002

30 Kusum Devi, V, "Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride" 29 : 495-503, 2003

31 Hayton, W. L, "Correction of perfusate concentration for sample removal" 71 : 820-821, 1982

32 Moffat, A. C, "Clarke's Analysis of Drugs and Poisons. Third Edition" Pharmaceutical Press 2005